ARREST - A Phase I Study of SABR for Poly-metastatic Disease

Official Title

ARREST - A Phase I Study of SABR for Poly-metastatic Disease

Summary:

Stereotactic ablative radiation therapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small areas in the body. This new technique can potentially allow radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. This improvement could help by reducing side effects overall (through radiation exposure to a smaller area of the body over a shorter time period), and by improving the chance of controlling the cancer by more precisely treating the cancer and by giving higher doses of radiation. SABR is considered a standard treatment for some lung cancers, and selected cancers that have spread to the brain. Ongoing studies are evaluating the use of SABR for treating people with up to 10 sites of cancer in the body, but its safety and value for treating patients with poly-metastatic cancer (more than 10 sites of cancer) is not yet known. The purpose of this study is to determine the safety of using SABR to treat people with poly-metastatic disease. To our knowledge, this is the first time that SABR will be tested in people who have poly-metastatic disease.

Trial Description

Primary Outcome:

• Maximally Tolerated Dose of Stereotactic Radiation Therapy

• Quality of life at 6 weeks post radiation therapy as measured by the Functional Assessment of Cancer Therapy - General (FACT-G)
• Quality of life at 6 weeks post radiation therapy as measured by the EuroQOL Group EQ-5D-5L
• Progression free survival post radiation therapy

View this trial on ClinicalTrials.gov